SEATTLE, March 10, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the completion of a debt financing with Leste Clearway and Serengeti Asset Management. The combined financing provides $5.5M of capital to support integration, growth, and commercial expansion of the LumiThera… Continue reading →

SEATTLE, March 3, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the completion of its acquisition of Diopsys, Inc., a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual… Continue reading →

SEATTLE, Nov. 11, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced its entry into a definitive merger agreement with Diopsys, Inc., a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual… Continue reading →

SEATTLE, July 21, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients. A total of 23 eyes from 15 subjects with Dry AMD were enrolled into the… Continue reading →

SEATTLE, May 7, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research investigators lead by Drs. Hakan Kaymak, Inken Becker and Hartmut Schwahn, from the Macula Retina Centre of Breyer Kaymak & Klabe Eye Clinic in Dusseldorf, Germany presented positive clinical… Continue reading →

SEATTLE, April 7, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration (AMD) patients. The prospective, double-masked, randomized, multi-center, European Union post-marketing clinical trial, titled LIGHTSITE II, was… Continue reading →

SEATTLE, Feb. 16, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate Dry AMD were enrolled into the prospective… Continue reading →

LumiThera is a Poulsbo-based medical device company that harnesses the healing power of light. Founded by Clark E. Tedford, Ph.D. and a team of two eye doctors and two engineers, LumiThera was conceived with the goal of developing a noninvasive treatment for degenerative eye disease. Tedford has more than 30 years of experience in the… Continue reading →

SEATTLE, Feb 10, 2021 /PRNewswire/ — LumiThera, Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed enrollment in its multi-center United States clinical study in non-neovascular (dry) Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center study, LIGHTSITE III, enrolled the last patient at the Byers Eye Institute… Continue reading →